Sermorelin is a synthetic analog of growth hormone–releasing hormone (GHRH), consisting of the first 29 amino acids of the natural 44-amino acid peptide. It stimulates the pituitary gland to produce and release endogenous growth hormone (GH), which in turn increases insulin-like growth factor 1 (IGF-1) levels. Sermorelin has been studied for its potential roles in aging, body composition, and recovery.
It was previously FDA-approved for diagnosing GH deficiency in children, but this approval was later withdrawn. Sermorelin remains experimental and is not currently FDA-approved for therapeutic use.
How It Is Used in Research Settings
- Studied for stimulating endogenous GH release in models of aging and GH deficiency.
- Explored for supporting lean body mass, fat metabolism, and recovery in metabolic studies.
- Investigated for its potential neuroprotective and regenerative effects through GH/IGF-1 pathways.
- Examined in sleep and circadian rhythm research due to GH’s role in restorative processes.
Proposed Uses (Research Areas)
- Aging and longevity research.
- Metabolic health — fat loss, lean muscle preservation.
- GH deficiency models and endocrine studies.
- Recovery and regenerative medicine research.
How It Is Dosed in Research Settings
- Injectable: Typical research dosing is 100–500 mcg subcutaneously once daily, often at night to mimic natural GH release patterns.
- Cycle length: Protocols usually last 8–12 weeks, though some extend longer in aging research models.
- Combination protocols: Sometimes studied alongside GHRPs (e.g., GHRP-2, GHRP-6, Ipamorelin) to enhance pulsatile GH release.
- Handling: Supplied as lyophilized powder; reconstituted with bacteriostatic water and stored refrigerated per research SOPs.
Important Considerations
- Regulatory status: Formerly FDA-approved for pediatric diagnostic use; no longer approved for medical use. Current applications are experimental.
- Evidence base: Data supports its ability to stimulate GH release; broader clinical benefits remain under investigation.
- Safety: Reported research side effects include flushing, headache, and injection site irritation. Long-term safety requires more study.
Disclaimer
This material is provided for educational purposes only and summarizes published research on Sermorelin.
It is not medical advice. Sermorelin is experimental, not FDA-approved, and should not be viewed as a therapy for medical use.
This peptide is for research use only.